Core Insights - Anixa Biosciences is conducting a Phase 1 clinical trial for its CAR-T therapy targeting recurrent ovarian cancer, with the second patient in the fourth dose cohort treated successfully [1][3] - The fourth cohort is receiving a dose of three million CAR-positive cells per kilogram, a 30-fold increase from the initial dose, with no dose-limiting toxicities observed to date [2][4] - The CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells and certain cancer cells, indicating a potential for targeted therapy [3][4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a proprietary CAR-T program developed in collaboration with Moffitt Cancer Center [5] - The CAR-T technology is differentiated by its use of the natural ligand of the FSHR receptor, FSH, which binds directly to tumor cells rather than using an antibody fragment [5] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in cancer [5]

Core Insights - Anixa Biosciences has received a new patent extending the protection of its CAR-T technology to 2045, enhancing its intellectual property portfolio [1][2][3] - The patent covers fundamental methods and compositions essential to Anixa's CAR-T approach, which aims to tackle challenges in treating solid tumors [2] - Anixa's CAR-T technology is currently in clinical trials for recurrent ovarian cancer at Moffitt Cancer Center, indicating progress in its therapeutic development [2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a unique CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) [3] - The company collaborates with leading research institutions, such as Moffitt Cancer Center and Cleveland Clinic, to develop its therapeutic and vaccine portfolios [3] - Anixa's vaccine programs target various cancers, including breast and ovarian cancer, and utilize innovative approaches to immunization [3]

Core Insights - Anixa Biosciences, Inc. is advancing its CAR-T therapy for ovarian cancer, with Dr. Robert Wenham as the principal investigator for the ongoing Phase 1 clinical trial [1][4] - Dr. Wenham will present at the 13th Annual Ovarcoming Cancer Conference, discussing advancements in ovarian cancer research and therapies, including Anixa's CAR-T therapy [2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor [4] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [4] Conference Details - The Ovarcoming Cancer Conference aims to unite survivors, caregivers, and medical professionals to learn from experts in the ovarian cancer field [3] - Dr. Wenham's presentation is scheduled for September 18, 2025, from 12:05 PM to 12:30 PM CT [2]

Core Insights - Anixa Biosciences has initiated the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine, which is currently held by Cleveland Clinic, to advance to a Phase 2 clinical trial [1][2][4] - The Phase 1 clinical trial has shown promising results, with over 70% of patients exhibiting immune responses, indicating the vaccine's potential effectiveness [2][4] - The breast cancer vaccine targets α-lactalbumin, a protein associated with lactation that re-emerges in many breast cancer forms, suggesting both therapeutic and preventive benefits [3][4] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines for breast and ovarian cancer, as well as other cancers, utilizing technologies that target proteins expressed in certain cancer forms [5] - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [5]

Core Insights - Anixa Biosciences has received a Notice of Allowance for a new patent in Canada related to its breast cancer vaccine technology, enhancing its international intellectual property portfolio [1][2][3] - The patent provides composition-of-matter protection for Anixa's immunogenic approach to breast cancer prevention and treatment, which is exclusively licensed from Cleveland Clinic [1][4] - Breast cancer is the most commonly diagnosed cancer in women globally, accounting for approximately 25% of new cancer cases in women in Canada and 13% of female cancer deaths annually [3] Intellectual Property Expansion - The newly allowed Canadian patent complements existing and pending patents in the United States and other key global jurisdictions, reinforcing Anixa's leadership in cancer immunoprevention [2][5] - This expansion of the patent estate is crucial for future regulatory and commercial efforts outside the U.S., positioning the company for strategic global opportunities [2][3] Vaccine Technology - Anixa's breast cancer vaccine targets human α-lactalbumin, a protein aberrantly expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation while sparing normal tissue [4][5] - The company's broader vaccine platform also addresses other high-incidence cancers, transforming the approach to cancer prevention in the medical community [5] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [6] - The company partners with renowned research institutions to develop vaccines targeting various cancers, including breast and ovarian cancer, utilizing a unique business model that allows for continuous examination of emerging technologies [6]

Company Overview - ANIXA BIOSCIENCES INC is part of the Medical group, which consists of 984 companies and ranks 8 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 492 companies and currently ranks 95 in the Zacks Industry Rank [6] Performance Metrics - ANIXA BIOSCIENCES INC has gained approximately 45.3% year-to-date, significantly outperforming the average loss of 2.9% in the Medical group [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has increased by 7.3% over the past quarter, indicating improved analyst sentiment [4] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the next one to three months [3] Comparative Analysis - Another stock in the Medical sector, Mind Medicine (MindMed) Inc. (MNMD), has also shown strong performance with a year-to-date return of 39.7% and a Zacks Rank of 2 (Buy) [5] - Both ANIXA and Mind Medicine belong to the same industry, with the latter's consensus EPS estimate increasing by 4.3% over the past three months [5][6] Future Outlook - Investors interested in Medical stocks should monitor ANIXA BIOSCIENCES INC and Mind Medicine (MindMed) Inc. for potential continued strong performance [7]

Core Viewpoint - Anixa Biosciences has received a patent for its breast cancer vaccine technology, which addresses a significant unmet need in preventive oncology and has the potential for a multi-billion dollar market opportunity [1][2][5]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [7]. - The company has a unique business model of partnering with renowned research institutions for all stages of development, allowing for continuous examination of emerging technologies [7]. Patent and Technology - The U.S. Patent Number 12,370,244 will be issued on July 29, 2025, covering methods of immunizing patients against breast cancer using human α-lactalbumin protein [1][2]. - The patent extends foundational protection for the breast cancer vaccine program into the mid-2040s, enhancing Anixa's ability to develop and commercialize immunopreventive solutions [2][6]. Market Opportunity - The breast cancer vaccine platform represents a potential multi-billion dollar market, particularly for women at elevated risk of developing triple-negative breast cancer (TNBC) [5]. - In the U.S., over 297,000 new cases of invasive breast cancer are projected in 2025, highlighting the significant need for preventive solutions [3]. Vaccine Mechanism - The investigational vaccine aims to stimulate the immune system to recognize and eliminate pre-malignant and malignant cells expressing α-lactalbumin while sparing normal tissue [4]. - By targeting this protein, which is generally absent from adult tissues except during lactation, the vaccine may minimize off-target effects and provide long-lasting immune protection [4].

Company Overview - Anixa Biosciences, Inc. (NASDAQ: ANIX) focuses on developing immunotherapies for cancer through two main platforms: a CAR-T program aimed at solid tumors and a vaccine technology that generates tumor-specific antigens [1]. Partnerships - Anixa has established partnerships with the Moffitt Cancer Center, which may enhance its research and development capabilities in the field of cancer immunotherapy [1].

Company Performance - ANIXA BIOSCIENCES INC has gained approximately 35.4% year-to-date, significantly outperforming the Medical group, which has lost about 4.1% on average [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has increased by 7.3% over the past 90 days, indicating improved analyst sentiment and a more positive earnings outlook [3] Industry Context - ANIXA BIOSCIENCES INC is part of the Medical - Biomedical and Genetics industry, which includes 495 companies and currently ranks 75 in the Zacks Industry Rank. This industry has experienced an average loss of 2% year-to-date, showing that ANIX is performing better than its peers [6] - In comparison, CochLear Ltd. Unsponsored ADR, another outperforming stock in the Medical sector, has returned 9.6% since the beginning of the year and is part of the Medical Services industry, which has moved -2.4% year-to-date and ranks 64 [4][7]

Core Viewpoint - Anixa Biosciences has announced the issuance of a key patent for its ovarian cancer vaccine technology, which is expected to enhance the company's position in the cancer treatment market [1][4]. Group 1: Patent and Technology - The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025, covering methods related to eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2) [1]. - The patent includes methods for administering an immunogenic composition that encodes the AMHR2 polypeptide, specifically targeting the extracellular domain of human AMHR2 [3]. - Anixa holds exclusive worldwide rights to the patent, which was issued to Cleveland Clinic [3]. Group 2: Collaboration and Development - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2]. - Anixa's therapeutic portfolio includes an ovarian cancer immunotherapy program utilizing chimeric endocrine receptor-T cell (CER-T) technology, which is distinct from traditional CAR-T therapies [4]. - The company is also developing additional cancer vaccines in collaboration with Cleveland Clinic to address various cancers, including breast, lung, colon, and prostate cancers [4].